April 5, 2018 - A Massachusetts federal judge gave her initial approval Thursday to Impax Laboratories Inc.’s $20 million mid-trial settlement with a class of consumers and insurers.
The suit claimed that Impax unlawfully delayed the launch of its generic acne medicine for three years in exchange for a $40 million payment from Medicis Pharmaceutical Corp., the maker of Solodyn.
Judge Casper said the settlement “was concluded after arm’s-length negotiations by experienced counsel on behalf of the certified end-payor class.”
The settlement with Impax marks the conclusion of the case. Before trial, the “end-payor” class reached settlements with the other defendants totaling $23 million.